<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03669406</url>
  </required_header>
  <id_info>
    <org_study_id>35RC17_8999_FATSCAR</org_study_id>
    <secondary_id>2017-A03022-51</secondary_id>
    <nct_id>NCT03669406</nct_id>
  </id_info>
  <brief_title>Feasibility Study - The Place of Surgical Management by Fatty Autograft in Patients With Healed Pelvic Eschar. Interest in Secondary Prevention.</brief_title>
  <acronym>FATSCAR</acronym>
  <official_title>Feasibility Study - The Place of Surgical Management by Fatty Autograft in Patients With Healed Pelvic Eschar. Interest in Secondary Prevention.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Autografting of fat cells is widely used in plastic surgery in breast reconstruction, burn
      scars, unsightly scars etc. It is known that the autografting of fat cells not only makes it
      possible to bring adipocytes, and thus to create a volume, but also promotes neo-angiogenesis
      by providing the growth factors which allows an improvement of the local cutaneous tissue.

      Currently the investigators perform this action in their service on healed eschars, by
      analogy with burn scars that are also dystrophic, so as to improve cutaneous trophicity, and
      reduce the recurrence of eschars on these scars. However, the literature on the autografting
      of fat cells on eschars is limited.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2020</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of recurrence of eschar</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of occurrence of recurrence of eschar (censored criterion)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POSAS scale score</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vancouver score</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement Vancouver score</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of recurrence of eschar</measure>
    <time_frame>12 months</time_frame>
    <description>Clinical evaluation : non-recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of neovascularization</measure>
    <time_frame>12 months</time_frame>
    <description>by Speckle laser doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volumetric assessment</measure>
    <time_frame>12 months</time_frame>
    <description>by contouring MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of pro-angiogenic genes expressed in the stromal vascular fraction of the injected fat</measure>
    <time_frame>12 months</time_frame>
    <description>RNA PCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of the stromal vascular fraction of the injected fat</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Eschar</condition>
  <arm_group>
    <arm_group_label>Autograft fat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paraplegic patients with healed pelvic eschar</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autograft fat</intervention_name>
    <description>autograft fat</description>
    <arm_group_label>Autograft fat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient between 18 and 65 years old;

          -  presenting a medullary, post-traumatic or congenital lesion, with consequent
             paraplegic sequelae;

          -  With a history of eschar:

               -  Pelvic (ischiatic, trochanteric or sacral),

               -  Healed for at least 6 months, after surgical treatment or directed healing
                  (scarring is defined by the absence of local care, ie no nursing care);

          -  Affiliated to a social security ;

          -  Written informed consent.

        Exclusion Criteria:

          -  Patient malnourished (albuminemia &lt;40g / L);

          -  Non-weaning or weaned tobacco addiction for less than 3 weeks (compared to the date of
             surgery);

          -  Contraindication to MRI ;

          -  Protected person subject to legal protection (legal safeguards, guardianship,
             trusteeship), person deprived of liberty,

          -  Pregnant woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie AILLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cécile MEAL</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Rennes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pascal Gaudron</last_name>
    <phone>02 99 28 25 55</phone>
    <email>drc@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Ganivet</last_name>
    <phone>02 99 28 25 55</phone>
    <email>anne.ganivet@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cécile Méal</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>September 10, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healed pelvic eschar</keyword>
  <keyword>Paraplegic patient</keyword>
  <keyword>Fat autograft</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

